Merck handed $200m in Gilead hepatitis C row

29-03-2016

Merck handed $200m in Gilead hepatitis C row

STILLFX / Shutterstock.com

Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.


Merck, Gilead, patent, damages, Sovaldi, Harvoni, sofosbuvir, US District Court for the Northern District of California

LSIPR